Abstracts tagged "giant cell arteritis"

Abstract Number: 9L • 2015 ACR/ARHP Annual Meeting
A Randomized Double-Blind Trial of Abatacept and Glucocorticoids for the Treatment of Giant Cell Arteritis
Carol A. Langford¹, David Cuthbertson², Steven R. Ytterberg³, Nader A. Khalidi⁴, Paul A. Monach⁵, Simon Carette⁶, Philip Seo⁷, Larry W. Moreland⁸, Michael Weisman⁹, Curry L. Koening¹⁰, Antoine G. Sreih¹¹, Robert F. Spiera¹², Carol McAlear¹³, Kenneth J. Warrington¹⁴, Christian Pagnoux⁶, Kathleen Maksimowicz-McKinnon¹⁵, Lindsy J. Forbess¹⁶, Gary S. Hoffman¹, Renee Borchin¹⁷, Jeffrey Krischer¹⁷ and Peter A. Merkel¹⁸, ¹Rheumatology, Cleveland Clinic, Cleveland, OH, ²Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ³Rheumatology Division, Mayo Clinic, Rochester, MN, ⁴McMaster University, St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ⁵Rheumatology, Boston University School of Medicine, Boston, MA, ⁶Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁷Division of Rheumatology, Johns Hopkins, Baltimore, MD, ⁸Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁹Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁰Division of rheumatology, George E. Wahlen Department of Veterans Affairs Medical Center Salt Lake City and University of Utah, University of Utah School of Medicine, Salt Lake City, UT, ¹¹Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology, Mayo Clinic, Rochester, MN, ¹⁵Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ¹⁷University of South Florida, Tampa, FL, ¹⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel primary systemic vasculitis. Although glucocorticoids are effective in treating GCA, they are associated with substantial toxicity and…
Abstract Number: 200 • 2015 ACR/ARHP Annual Meeting
Mast Cell Regulation of Aortic IL-6 Expression Involves Histamine-1 Receptor, Suppressor of Cyotkine Signaling-1 and IL-10
Vineesh Raveendran¹, Jason Springer², Donald Smith³, Mehrdad Maz⁴ and Kottarappat Dileepan¹, ¹Department of Medicine, University of Kansas Medical Center, Kansas City, KS, ²Division of Allergy, Clinical Immunology and Rheumatology, University of Kansas Medical Center, Kansas City, KS, ³University of Kansas Medical Center, Kansas City, KS, ⁴Division of Rheumatology, University of Kansas Medical Center, Kansas City, KS
Background/Purpose: IL-6 plays an important role in the pathogenesis of large vessel vasculitis. Lipopolysaccharide (LPS), acting through toll-like receptor 4, enhances both the aortic expression…
Abstract Number: 1980 • 2015 ACR/ARHP Annual Meeting
Tocilizumab in Giant Cell Arteritis: A Multicentre Open-Label Study in France
Alexis Regent¹, Serge Redeker², Alban Deroux³, Pierre Kieffer⁴, Kim Heang Ly⁵, Maxime Dougados⁶, Claire Larroche⁷, Loïc Guillevin¹, Laurence Bouillet⁸, Olivier Espitia⁹, Nathalie Costedoat-Chalumeau¹⁰, Martin Soubrier¹¹, Benoit Brihaye¹², François Lifermann¹³, Guillaume Lefèvre¹⁴, Xavier Puéchal¹, Luc Mouthon¹, Eric Toussirot¹⁵ and GFEV and CRI, ¹Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, Paris, France, ²43 rue de l'isle, Ch Abbeville, Abbeville, France, ³Internal Medicine, CHU Grenoble, Grenoble, France, ⁴Hopital Emile Muller, Mulhouse Cedex 1, France, ⁵CHU de Limoges, Service de médecine interne, Limoges, France, ⁶Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ⁷Internal Medicine, Paris, France, ⁸CHU, Grenoble, France, ⁹Internal Medicine, Nantes University Hospital, Nantes, France, ¹⁰Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ¹¹Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ¹²Service de médecine interne et médecine polyvalente, Saint Quentin, France, ¹³CH Dax, Dax, France, ¹⁴Service de médecine interne, Centre National de Référence de la Sclérodermie Systémique, Hôpital Claude Huriez, CHRU Lille, Lille, France, ¹⁵Service de Rhumatologie, CHU J Minjoz, Besancon, France
Background/Purpose: To report the French experience on the efficacy and safety of tocilizumab (TCZ) in patients with giant cell arteritis (GCA) and outcome after treatment…
Abstract Number: 1233 • 2015 ACR/ARHP Annual Meeting
Epidemiology of GCA in Bergen (Western Norway) 1972-2012
Lene K Brekke¹, Andreas P Diamantopoulos², Elisabet L Esperø¹, Bjørg-Tilde Fevang^3,4, Johan G Brun^3,4 and Clara G Gjesdal^3,4, ¹Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ²Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway, ³Department of Rheumatology, Haukeland University Hospital, Bergen, Norway, ⁴Department of Clinical Science, University of Bergen, Bergen, Norway
Background/Purpose: Giant cell arteritis (GCA) is the most common systemic vasculitis in persons older than 50 years. The highest incidence rates of the disease have…
Abstract Number: 2156 • 2015 ACR/ARHP Annual Meeting
Damage Assessment in Giant Cell Arteritis
Tanaz A. Kermani¹, Antoine G. Sreih², David Cuthbertson³, Simon Carette⁴, Gary S. Hoffman⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol A. Langford⁵, Carol A. McAlear⁸, Paul A. Monach⁹, Larry W. Moreland¹⁰, Christian Pagnoux⁴, Philip Seo¹¹, Kenneth J. Warrington¹², Steven R. Ytterberg¹² and Peter A. Merkel¹³, ¹Rheumatology, University of California Los Angeles, Santa Monica, CA, ²Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁴Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Rheumatology, Cleveland Clinic, Cleveland, OH, ⁶McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, University of Utah, Salt Lake City, UT, ⁸Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Rheumatology, Mayo Clinic, Rochester, MN, ¹³Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: This study aimed to 1) catalogue damage in a longitudinal cohort of patients with giant cell arteritis (GCA) and 2) evaluate predictors of…
Abstract Number: 1340 • 2015 ACR/ARHP Annual Meeting
Value of 18F-FDG PET for Therapeutic Assessment in Patients with Polymyalgia Rheumatica Treated in First Line By Tocilizumab
Xavier Palard¹, Solene Querellou², Maelenn Gouillou³, Alain Saraux^4,5, Thierry Marhadour⁶, Florent Garrigues⁷, Ronan Abgral⁸, Pierre-Yves Salaun⁸ and Valerie Devauchelle^9,10, ¹Department of nuclear medicine, University hospital of Brest, Brest, France, ²Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, French Polynesia, ³Clinical Investigation Centre (CIC) 1412, CHU Cavale Blanche- Institut National de la Santé et de la Recherche Médicale (INSERM), Brest, France, ⁴Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁵Rheumatology Department, CHU de la Cavale Blanche, Brest Cedex, France, ⁶CHU La Cavale Blanche, Brest, France, ⁷Radiology department, Cavale Blanche Hospital and Brest Occidentale University, Brest, France, ⁸Department of nuclear medicine, Université Européenne de Bretagne; Université de Brest; EA3878 (GETBO) IFR148, Brest, France, ⁹Service de Rhumatologie, CHU Brest, Brest, France, ¹⁰Rheumatology, Brest university medical school, EA 2216, UBO and CHU de la Cavale Blanche,, Brest, France
Background/Purpose: To evaluate the interest of 18F-FDG positron emission tomography-computed tomography (PET-CT) for therapeutic assessment in polymyalgia rheumatica (PMR) patients undergoing tocilizumab (TCZ) therapy at first…
Abstract Number: 2157 • 2015 ACR/ARHP Annual Meeting
Relapse Characteristics and Glucocorticoid Use in Patients with Biopsy-Proven Giant Cell Arteritis
Matthew J. Koster¹, Cristian Labarca², Cynthia S. Crowson³, Ashima Makol¹, Steven R. Ytterberg⁴, Eric L. Matteson¹ and Kenneth J. Warrington¹, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Rheumatology Division, Mayo Clinic, Rochester, MN
Background/Purpose: Relapses in patients with giant cell arteritis (GCA) are common and often lead to higher cumulative use of glucocorticoids. This study aims to evaluate…
Abstract Number: 1953 • 2015 ACR/ARHP Annual Meeting
Identification of Genetic Factors Associated with Clinical Manifestations of Giant Cell Arteritis through a Stratified Large-Scale Analysis
Ana Márquez¹, Francisco David Carmona², Maria C. Cid³, José Hernández-Rodríguez³, Roser Solans⁴, Marc Ramentol⁴, Santos Castañeda⁵, Jose A. Miranda-Filloy⁶, Inmaculada C. Morado⁷, Javier Narváez⁸, Eugenio De Miguel⁹, Bernardo Sopeña¹⁰, Jordi Monfort¹¹, Maria Jesus Garcia-Villanueva¹², Norberto Ortego-Centeno¹³, Miguel Angel Gonzalez-Gay¹⁴, Javier Martín¹⁵ and Spanish GCA Group, ¹Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada and Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ²Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain, ³Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clínic University of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, ⁴Autoimmune Systemic Diseases Unit, Department of Internal Medicine, Hospital Vall d’Hebron, Autonomous University of Barcelona, Barcelona, Spain, ⁵Department of Rheumatology, Hospital de la Princesa, IIS-Princesa, Madrid, Spain, ⁶Department of Rheumatology, Hospital Xeral-Calde, Lugo, Spain, ⁷Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ⁸Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹Department of Rheumatology, Hospital Universitario La Paz, Madrid, Spain, ¹⁰Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ¹¹Department of Rheumatology, Grup de recerca cel•lular en inflamació i cartílag. IMIM (Institut de Recerca Hospital del Mar), Barcelona, Spain, ¹²Department of Rheumatology, Hospital Ramón y Cajal, Madrid, Spain, ¹³Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, ¹⁴Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Santander, Spain, ¹⁵Instituto de Parasitología y Biomedicina López- Neyra, IPBLN-CSIC, PTS-Granada, Granada, Spain
Background/Purpose: Giant cell arteritis (GCA) is a large-vessel vasculitis that primarily affects the aorta and external carotid arteries and their branches, leading to ischemic manifestations…
Abstract Number: 2159 • 2015 ACR/ARHP Annual Meeting
Second Temporal Artery Biopsies in Patients with Temporal Arteritis (TA)
John Fritzlen¹, Brian Younge², Cornelia M. Weyand³, Gene G. Hunder⁴, Jorg Goronzy⁵, Kenneth J. Warrington⁴ and Joseph Maleszewski¹, ¹Anatomical Pathology, Mayo Clinic, Rochester, MN, ²Ophthalmology, Mayo Clinic, Rochester, MN, ³Stanford, Stanford, CA, ⁴Rheumatology, Mayo Clinic, Rochester, MN, ⁵Emory University School of Medicine, Lowance Center for Human Immunology and Rheumatology, Atlanta, GA
Background/Purpose: While many manifestations of TA improve quickly after starting glucocorticoid therapy, vascular inflammation appears to persist. To obtain more information about the duration of…
Abstract Number: 1954 • 2015 ACR/ARHP Annual Meeting
How Can We Use Ultrasound in the Diagnosis and Management of Patients with Giant Cell Arteritis?
Cristina Ponte^1,2, Sophie Vaggers¹, Jan Sznajd¹, Lorraine O'Neill¹, Jennifer Piper³, Jessica Gunn¹, Kulveer Mankia¹ and Raashid Luqmani¹, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²Rheumatology and Metabolic Bone Diseases Department, Rheumatology Research Unit - IMM, Lisbon Academic Medical Centre, Lisbon, Portugal, ³Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom
Background/Purpose: Giant cell arteritis (GCA), the most common primary vasculitis, can cause irreversible blindness in 20-30% of untreated cases, but glucocorticoid therapy leads to significant…
Abstract Number: 2161 • 2015 ACR/ARHP Annual Meeting
Ustekinumab for the Treatment of Refractory Giant Cell Arteritis
Richard Conway^1,2, Lorraine O'Neill^3,4, Eileen O'Flynn³, Geraldine M. McCarthy^5,6, Conor Murphy⁷, Douglas J. Veale⁸, Ursula Fearon⁹ and Eamonn S. Molloy¹⁰, ¹CARD Newman Research Fellow, University College Dublin, Dublin, Ireland, ²Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, University College Dublin, Dublin, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ⁴Rheumatology, St. Vincent's University Hospital, Dublin 4, Ireland, ⁵Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ⁶University College Dublin, Dublin, Ireland, ⁷Department of Ophthalmology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland, ⁸St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ⁹St. Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, Dublin 4, Ireland, ¹⁰St Vincent's University Hospital, Centre for Arthritis and Rheumatic Diseases, Dublin Academic Medical Centre, St Vincent's University Hospital, Dublin 4, Dublin 4, Ireland
Background/Purpose: Giant cell arteritis (GCA) requires treatment with high dose corticosteroids. Many patients require chronic steroid therapy with associated significant side effects. There is a…
Abstract Number: 1958 • 2015 ACR/ARHP Annual Meeting
Diagnostic Value of Ultrasonography-Derived Signs in Giant Cell Arteritis: Literature Review and Meta-Analysis
Fanny BUSQUET¹, Léa Rouxel², Thomas Barnetche³ and Thierry Schaeverbeke⁴, ¹intern of hospital, BORDEAUX, France, ²intern of hospital, Bordeaux, France, ³PHD, bordeaux, France, ⁴department head, Bordeaux, France
Background/Purpose: Giant Cell Arteritis (GCA) is the most common form of systemic inflammatory vasculitis in elderly people, with prevalence still increasing, and for which there…
Abstract Number: 1960 • 2015 ACR/ARHP Annual Meeting
a Structured and Extensive Training Program on Vascular Ultrasound, Results in an Excellent Agreement Between Ultrasound and Temporal Artery Biopsy in the Diagnosis of Giant Cell Arteritis
Stavros Chrysidis¹, Ulrich Fredberg², Uffe Møller Døhn³, Tove Lorenzen⁴, Lene Terslev⁵, Knud Larsen⁶ and Andreas P Diamantopoulos⁷, ¹Department of Rheumatology, Hospital of Southwest Denmark, Esbjerg, Denmark, ²Department of Internal Medicine, Diagnostic Centre Region Hospital Silkeborg Denmark, Silkeborg, Denmark, ³Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Glostrup, Denmark, ⁴Diagnostic Centre, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Copenhagen University Hospital at Glostrup, Copenhagen, Denmark, ⁶otolaryngology, Southwest hospital, Esbjerg, Denmark, ⁷Rheumatology, Haugesund Hospital for Rheumatic Diseases, Haugesund, Norway
Background/Purpose: There is an increased use of vascular ultrasound (US) for diagnosing giant cell arteritis (GCA). Consequently, extensive and structured training of ultrasonographers performing vascular…
Abstract Number: 1962 • 2015 ACR/ARHP Annual Meeting
Inter-Rater Analysis of Ultrasound and Histological Findings in Patients with Suspected Giant Cell Arteritis
Raashid Luqmani¹, Ellen Lee², Surjeet Singh³, Michael Gillett², Wolfgang A. Schmidt⁴, Mike Bradburn², Bhaskar Dasgupta⁵, Andreas P Diamantopoulos⁶, Wulf Forrester-Barker⁷, William Hamilton⁸, Shauna Masters⁹, Brendan McDonald¹⁰, Eugene McNally⁷, Colin T. Pease¹¹, Jennifer Piper⁷, John Salmon¹², Allan Wailoo², Konrad Wolfe¹³, Andrew Hutchings¹⁴ and TABUL Sonographers Group and TABUL Pathologists Group, ¹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²School of Health and Related Research, University of Sheffield, Sheffield, United Kingdom, ³1Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁴Medical Center for Rheumatology and Clinical Immunology Berlin-Buch, Immanuel Krankenhaus Berlin, Berlin, Germany, ⁵Rheumatology, Southend University Hospital, Essex, United Kingdom, ⁶Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ⁷Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁸Primary Care, University of Exeter, Exeter, United Kingdom, ⁹Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Science, University of Oxford, Oxford, United Kingdom, ¹⁰Department of Neuropathology and Ocular Pathology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹¹Rheumatology, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ¹²Ophthalmology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom, ¹³Department of Pathology, Southend University Hospital, Essex, United Kingdom, ¹⁴Health Services Research Unit, London School of Hygiene and Tropical Medicine, London, United Kingdom
Background/Purpose: Ultrasound is emerging as an alternative test to performing a temporal artery biopsy in the diagnosis of giant cell arteritis (GCA). Little is known…
Abstract Number: 1965 • 2015 ACR/ARHP Annual Meeting
T Cell Activation, Proliferation and Differentiation Markers Lack Diagnostic Accuracy for Detecting Active GCA and PMR
Kornelis S.M. van der Geest¹, Wayel H. Abdulahad², Qi Wang², Mirjam Roffel², Gerda Horst², Abraham Rutgers², Annemieke M.H. Boots² and Elisabeth Brouwer², ¹Dept. of Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²Rheumatology and Clinical Immunology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands
Background/Purpose: The most important biomarker in GCA and PMR patients is increased erythrocytes sedimentation rate (ESR) and/ or increased serum level of C-reactive protein (CRP).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].